Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Time-Dependent Effects in Chronic Urticaria: A Time-Series Perspective of Omalizumab Treatment

Author(s): Anna Tagka*, George I. Lambrou, Michael Makris, Evangelia Nakou, Electra Nicolaidou , Argyro Chatziioannou and Alexandra Katsarou

Volume 20, Issue 10, 2020

Page: [1726 - 1739] Pages: 14

DOI: 10.2174/1871530320666200313151720

Price: $65

Abstract

Background: Chronic spontaneous urticaria (CSU, or CU) is a disease that significantly affects the quality of life of patients. It is a chronic disease and requires a specialized approach to diagnosis and treatment. In recent years, the disease has been of great interest due to the existence of new targeted therapeutic approaches.

Aim: The present study aims at analyzing CU score concerning time, as a time-series. The authors have attempted to model the investigated time-series to unravel possible causative relationships.

Methods: 108 patients (25Males/83Females) admitted to our department were diagnosed with CU. CU was estimated on a score basis, which was used to define disease severity. Urticaria score was assessed on the basis of Urticaria Activity Score 7 (UAS7). The mean CU score, the mean CU score rate concerning the first month at diagnosis as well as the monthly CU score rate were calculated.

Results: Gender is a factor that influences CU score with time. In addition, there was a significant finding that time-series differ with the administration of monotherapy or complementary therapy.

Conclusion: We have found that females are more prone to CU, while omalizumab monotherapy has more beneficial results as compared to the application of concurrent and maintenance therapies. Further, patients with co-morbidities were more likely to interrupt treatment. Finally, and most significantly, it was shown that monthly CU score rate manifested an oscillatory pattern, which was modelled with the sum of sines functions, highlighting a relative immunological pattern.

Keywords: Chronic urticaria, omalizumab, dapsone, cyclosporine, time-series, modelling.

« Previous Next »
Graphical Abstract

[1]
Doutre, M. Physiopathology of urticaria. Eur. J. Dermatol., 1999, 9(8), 601-605.
[PMID: 10586124]
[2]
Asero, R.; Tedeschi, A.; Marzano, A.V.; Cugno, M. Chronic urticaria: a focus on pathogenesis. F1000 Res., 2017, 6, 1095.
[http://dx.doi.org/10.12688/f1000research.11546.1] [PMID: 28751972]
[3]
Beltrani, V.S. An overview of chronic urticaria. Clin. Rev. Allergy Immunol., 2002, 23(2), 147-169.
[http://dx.doi.org/10.1385/CRIAI:23:2:147] [PMID: 12221861]
[4]
Zuberbier, T.; Aberer, W.; Asero, R.; Abdul Latiff, A.H.; Baker, D.; Ballmer-Weber, B.; Bernstein, J.A.; Bindslev-Jensen, C.; Brzoza, Z.; Buense Bedrikow, R.; Canonica, G.W.; Church, M.K.; Craig, T.; Danilycheva, I.V.; Dressler, C.; Ensina, L.F.; Giménez-Arnau, A.; Godse, K.; Gonçalo, M.; Grattan, C.; Hebert, J.; Hide, M.; Kaplan, A.; Kapp, A.; Katelaris, C.H.; Kocatürk, E.; Kulthanan, K.; Larenas-Linnemann, D.; Leslie, T.A.; Magerl, M.; Mathelier-Fusade, P.; Meshkova, R.Y.; Metz, M.; Nast, A.; Nettis, E.; Oude-Elberink, H.; Rosumeck, S.; Saini, S.S.; Sánchez-Borges, M.; Schmid-Grendelmeier, P.; Staubach, P.; Sussman, G.; Toubi, E.; Vena, G.A.; Vestergaard, C.; Wedi, B.; Werner, R.N.; Zhao, Z.; Maurer, M. Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA²LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy, 2018, 73(7), 1393-1414.
[http://dx.doi.org/10.1111/all.13397] [PMID: 29336054]
[5]
Zuberbier, T.; Asero, R.; Bindslev-Jensen, C.; Walter Canonica, G.; Church, M.K.; Giménez-Arnau, A.; Grattan, C.E.; Kapp, A.; Merk, H.F.; Rogala, B.; Saini, S.; Sánchez-Borges, M.; Schmid-Grendelmeier, P.; Schünemann, H.; Staubach, P.; Vena, G.A.; Wedi, B.; Maurer, M. Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy, 2009, 64(10), 1417-1426.
[http://dx.doi.org/10.1111/j.1398-9995.2009.02179.x] [PMID: 19772512]
[6]
Zuberbier, T.; Maurer, M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm. Venereol., 2007, 87(3), 196-205.
[PMID: 17533484]
[7]
Maurer, M.; Magerl, M.; Metz, M.; Siebenhaar, F.; Weller, K.; Krause, K. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy, 2013, 68(6), 816-819.
[http://dx.doi.org/10.1111/all.12153] [PMID: 23646863]
[8]
Gaig, P.; Olona, M.; Muñoz Lejarazu, D.; Caballero, M.T.; Domínguez, F.J.; Echechipia, S.; García Abujeta, J.L.; Gonzalo, M.A.; Lleonart, R.; Martínez Cócera, C.; Rodríguez, A.; Ferrer, M. Epidemiology of urticaria in Spain. J. Investig. Allergol. Clin. Immunol., 2004, 14(3), 214-220.
[PMID: 15552715]
[9]
Simons, F.E.; Simons, K.J. Histamine and H1-antihistamines: celebrating a century of progress. J. Allergy Clin. Immunol., 2011, 128(6), 1139-1150.e4.
[http://dx.doi.org/10.1016/j.jaci.2011.09.005] [PMID: 22035879]
[10]
Jandoc, R.; Burden, A.M.; Mamdani, M.; Lévesque, L.E.; Cadarette, S.M. Interrupted time series analysis in drug utilization research is increasing: Systematic review and recommendations. J. Clin. Epidemiol., 2015, 68(8), 950-956.
[http://dx.doi.org/10.1016/j.jclinepi.2014.12.018] [PMID: 25890805]
[11]
Wagner, A.K.; Soumerai, S.B.; Zhang, F.; Ross-Degnan, D. Segmented regression analysis of interrupted time series studies in medication use research. J. Clin. Pharm. Ther., 2002, 27(4), 299-309.
[http://dx.doi.org/10.1046/j.1365-2710.2002.00430.x] [PMID: 12174032]
[12]
Davey, P.; Marwick, C.A.; Scott, C.L.; Charani, E.; McNeil, K.; Brown, E.; Gould, I.M.; Ramsay, C.R.; Michie, S. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst. Rev., 2017, 2CD003543
[http://dx.doi.org/10.1002/14651858.CD003543.pub4] [PMID: 28178770]
[13]
Ferrer, M.; Boccon-Gibod, I.; Gonçalo, M.; İnalöz, H.S.; Knulst, A.; Lapeere, H.; Parthasaradhi, A.; Stingl, G.; Tagka, A.; Valenzuela, F.; Yeung, J.; Thomsen, S.F. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria. Eur. J. Dermatol., 2017, 27(5), 455-463.
[http://dx.doi.org/10.1684/ejd.2017.3085] [PMID: 29084635]
[14]
Hollis, K.; Proctor, C.; McBride, D.; Balp, M.M.; McLeod, L.; Hunter, S.; Tian, H.; Khalil, S.; Maurer, M. Comparison of urticaria activity score over 7 days (uas7) values obtained from once-daily and twice-daily versions: Results from the assure-csu study. Am. J. Clin. Dermatol., 2018, 19(2), 267-274.
[http://dx.doi.org/10.1007/s40257-017-0331-8] [PMID: 29368043]
[15]
Młynek, A.; Zalewska-Janowska, A.; Martus, P.; Staubach, P.; Zuberbier, T.; Maurer, M. How to assess disease activity in patients with chronic urticaria? Allergy, 2008, 63(6), 777-780.
[http://dx.doi.org/10.1111/j.1398-9995.2008.01726.x] [PMID: 18445192]
[16]
Firooz, A.; Akhlaghi, A.; Golbidi, P.; Pourjafari, M.; Abdollahimajd, F.; Azimi, H.; Banihashemi, M.; Darvish Damavandi, F.; Erfani, A.R.; Farajzadeh, S.; Ghassemi, M.; Gheisari, M.; Hamedpour, K.; Handjani, F.; Hashemi, S.A.; Herizchi, H.; Iraji, F.; Jalili, H.; Khatami, A.; Lajevardi, V.; Mansouri, P.; Masjedi, H.; Mehrian, P.; Mohammadi, S.; Mohebbi, A.; Namazi, N.; Nasiri Kashani, M.; Radmehr, A.; Safar, F.; Saffarian, Z.; Saneei, S.; Seirafi, H.; Taheri, S.; Yazdanpanah, M.J.; Zaboli Nejad, N.; Naseri, M.; Peiravi, P.; Teymori, G. Real life management of chronic urticaria: Multicenter and cross sectional study on patients and dermatologists in Iran. Dermatol. Ther. (Heidelb.), 2019, 32(2)e12796
[http://dx.doi.org/10.1111/dth.12796] [PMID: 30520195]
[17]
Maillet, F.; Wolff, D.; Soria, A.; Adnet, F.; Panayotopoulos, V.; Gobert, D.; Lapostolle, F.; Reuter, P.G.; Ghazali, A.; Caux, F.; Fain, O.; Javaud, N. Factors associated with relapses among patients treated for acute urticaria. J. Dermatol., 2019, 46(5), 383-388.
[http://dx.doi.org/10.1111/1346-8138.14830] [PMID: 30816579]
[18]
Rosman, Y.; Hershko, A.Y.; Meir-Shafrir, K.; Kedem, R.; Lachover-Roth, I.; Mekori, Y.A.; Confino-Cohen, R. Characterization of chronic urticaria and associated conditions in a large population of adolescents. J. Am. Acad. Dermatol., 2019, 81(1), 129-135.
[http://dx.doi.org/10.1016/j.jaad.2019.02.034] [PMID: 30797847]
[19]
Liu, W.; Pan, X.; Vierkötter, A.; Guo, Q.; Wang, X.; Wang, Q.; Seité, S.; Moyal, D.; Schikowski, T.; Krutmann, J. A time-series study of the effect of air pollution on outpatient visits for acne vulgaris in beijing. Skin Pharmacol. Physiol., 2018, 31(2), 107-113.
[http://dx.doi.org/10.1159/000484482] [PMID: 29408821]
[20]
Hennino, A.; Bérard, F.; Guillot, I.; Saad, N.; Rozières, A.; Nicolas, J.F. Pathophysiology of urticaria. Clin. Rev. Allergy Immunol., 2006, 30(1), 3-11.
[http://dx.doi.org/10.1385/CRIAI:30:1:003] [PMID: 16461989]
[21]
McKeage, K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs, 2013, 73(11), 1197-1212.
[http://dx.doi.org/10.1007/s40265-013-0085-4] [PMID: 23812924]
[22]
Kaplan, A.P.; Giménez-Arnau, A.M.; Saini, S.S. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy, 2017, 72(4), 519-533.
[http://dx.doi.org/10.1111/all.13083] [PMID: 27861988]
[23]
Vonakis, B.M.; Saini, S.S. New concepts in chronic urticaria. Curr. Opin. Immunol., 2008, 20(6), 709-716.
[http://dx.doi.org/10.1016/j.coi.2008.09.005] [PMID: 18832031]

Rights & Permissions Print Cite
Article Metrics
24
© 2024 Bentham Science Publishers | Privacy Policy